Innate immunity and HBV persistence
- PMID: 33992859
- PMCID: PMC8319108
- DOI: 10.1016/j.coviro.2021.04.003
Innate immunity and HBV persistence
Abstract
Hepatitis B virus (HBV) causes chronic infections that are associated with immune dysfunction. Though T cell impairment is perhaps the most prominent immune change contributing to viral persistence, HBV interaction with the innate immune system is also likely key, as the lack of effective innate immunity has functional consequences that promote chronic infection. In addition to an intrinsic ability to fight viral infections, the innate immune system also impacts T cell responses and other adaptive immune mechanisms critical for HBV control. Therefore, it is essential to understand the relationships between HBV and innate immunity, as these interactions may be useful immunotherapeutic targets to manage the infection.
Copyright © 2021 Elsevier B.V. All rights reserved.
Conflict of interest statement
Competing interests statement
M.D.R. reports grants from NIH/NIAID during the conduct of the work, financial relationships with CaroGen Corporation, and research funding from Gilead Sciences outside of this work. In addition, M.D.R. has received royalties from a patent issued to Yale University. The other authors declare no competing interests.
Figures

Similar articles
-
Contribution of Toll-like receptors to the control of hepatitis B virus infection by initiating antiviral innate responses and promoting specific adaptive immune responses.Cell Mol Immunol. 2015 May;12(3):273-82. doi: 10.1038/cmi.2014.112. Epub 2014 Nov 24. Cell Mol Immunol. 2015. PMID: 25418467 Free PMC article. Review.
-
Adaptive immunity in HBV infection.J Hepatol. 2016 Apr;64(1 Suppl):S71-S83. doi: 10.1016/j.jhep.2016.01.026. J Hepatol. 2016. PMID: 27084039 Review.
-
The role of innate immunity in the immunopathology and treatment of HBV infection.J Hepatol. 2016 Apr;64(1 Suppl):S60-S70. doi: 10.1016/j.jhep.2016.01.028. J Hepatol. 2016. PMID: 27084038 Review.
-
Toward Curative Immunomodulation Strategies for Chronic Hepatitis B Virus Infection.ACS Infect Dis. 2019 May 10;5(5):703-712. doi: 10.1021/acsinfecdis.8b00297. Epub 2019 Apr 3. ACS Infect Dis. 2019. PMID: 30907080 Review.
-
HBV and the immune response.Liver Int. 2015 Jan;35 Suppl 1:121-8. doi: 10.1111/liv.12749. Liver Int. 2015. PMID: 25529097 Review.
Cited by
-
Toll-Like Receptor 7 Agonist RG7854 Mediates Therapeutic Efficacy and Seroconversion in Woodchucks With Chronic Hepatitis B.Front Immunol. 2022 May 23;13:884113. doi: 10.3389/fimmu.2022.884113. eCollection 2022. Front Immunol. 2022. PMID: 35677037 Free PMC article.
-
Recent advances in different interactions between toll-like receptors and hepatitis B infection: a review.Front Immunol. 2024 Mar 13;15:1363996. doi: 10.3389/fimmu.2024.1363996. eCollection 2024. Front Immunol. 2024. PMID: 38545106 Free PMC article. Review.
-
Anti-HBV treatment partially restores the dysfunction of innate immune cells and unconventional T cells during chronic HBV infection.Front Immunol. 2025 Jul 4;16:1611976. doi: 10.3389/fimmu.2025.1611976. eCollection 2025. Front Immunol. 2025. PMID: 40688073 Free PMC article. Review.
-
RDW-SD is Superior to RDW-CV in Reflecting Liver Fibrosis Stage in Patients with Chronic Hepatitis B.Infect Drug Resist. 2023 Oct 27;16:6881-6891. doi: 10.2147/IDR.S427047. eCollection 2023. Infect Drug Resist. 2023. PMID: 37920477 Free PMC article.
-
Tripartite Motif-Containing Protein 65 (TRIM65) Inhibits Hepatitis B Virus Transcription.Viruses. 2024 May 31;16(6):890. doi: 10.3390/v16060890. Viruses. 2024. PMID: 38932182 Free PMC article.
References
-
- Mutz P, Metz P, Lempp FA, Bender S, Qu B, Schoneweis K, Seitz S, Tu T, Restuccia A, Frankish J, et al.: HBV Bypasses the Innate Immune Response and Does Not Protect HCV From Antiviral Activity of Interferon. Gastroenterology 2018, 154:1791–1804. - PubMed
-
-
Suslov A, Boldanova T, Wang X, Wieland S, Heim MH: Hepatitis B Virus Does Not Interfere With Innate Immune Responses in the Human Liver. Gastroenterology 2018, 154:1778–1790.
**This study demonstrated a lack of IFN activation in ex vivo HBV patient liver biopsy samples, and also found no inhibition of the IFN response by HBV after exogenous stimulation.
-
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources